Teplizumab for Prevention of Type 1 Diabetes In Relatives At-Risk
AntiCD3 Mab (Teplizumab) For Prevention of Diabetes In Relatives At-Risk for Type 1 Diabetes Mellitus
Sponsor: American Diabetes Association
A PHASE2 clinical study on Autoantibody Positive and High Risk, this trial is completed. The trial is conducted by American Diabetes Association and has accumulated 12 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2019 — Sep 2020 [monthly]
Active Not Recruiting PHASE2
-
Aug 2018 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Sep 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Aug 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- American Diabetes Association
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Juvenile Diabetes Research Foundation
- National Center for Research Resources (NCRR)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Dallas, United States, Denver, United States, Gainesville, United States, Houston, United States, Indianapolis, United States, Kansas City, United States, Miami, United States, Minneapolis, United States, Munich, Germany, Nashville, United States and 8 more location s